Comparison of the Bioavailability of the Flavanol of Grape Extracts

NCT ID: NCT06665958

Last Updated: 2024-10-30

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-28
• Study Completion Date: 2025-09-01

Brief Summary

Polyphenols are a group of naturally occurring compounds found in cocoa, teas, and grape seed extracts (GSE) that have been linked to various health benefits. This study will provide a greater insight into the relationship between polyphenol consumption and health, and could be used to help with the development of functional food products and novel supplements. Although the advantages of a polyphenol-rich diet are well-established, the bioavailability of GSE (a source of polyphenols) in the context of human digestion and beneficial properties are poorly understood.

The investigators will conduct an open-label, randomized, 4-way crossover design with the aim to explore the bioavailability of GSE-derived flavan-3-ols from GSE and their related microbial metabolites and advance understanding of the bioactive properties of flavan-3-ols contributing to the development of more effective dietary strategies and functional food products.

Detailed Description

(Poly)phenols a complex class of naturally occurring compounds have garnered increasing attention due to their putative bioactive effects. Flavan-3-ols a subgroup of polyphenols, predominantly found in cocoa, various teas (including black and green tea), and grape seed extracts (GSE), have been associated with various health benefits including cardioprotective, neuroprotective, and anti-inflammatory effects. Moreover, their monomeric forms catechin and epicatechin have been increasingly investigated for their antioxidant properties, which may contribute to the prevention of chronic diseases such as cardiovascular disorders, diabetes, and neurodegenerative conditions. Increasing number of large-scale intervention trials have reported an inverse correlation between a flavan-3-ol intake in range of 400 - 800 mg/d and the risk of cardiovascular disease. A finding that has been supported by the recent COSMOS trial which included >20,000 participants who consumed 600 mg/d, reporting a significant 15% reduction in total CVD events when compared to the placebo group.

Despite these benefits, the efficacy of flavan-3-ols is heavily dependent on their bioavailability. However, this is severely influenced by various factors including the chemical structure, dosage, and the food matrix. Moreover, after ingestion, very few (poly)phenols are readily absorbed within the small intestine and subsequently not present in the circulation as the parent compound but as simpler phenolics, derived from the colonic fermentation within the large intestine where they are metabolised by the local microbiota through a series of chemical modifications such as ring fission, and cleavage of ester and/or glycosidic bonds. The newly formed simple phenolics may then undergo a various transformations mediated in part by local epithelial cell producing phase I/II metabolites such as, phenyl-y-valerolactones (PVLs) and their related phenylvaleric acids (PVAs), indicating that it is these secondary metabolites that offer the described benefits post-absorption. Although these metabolites are thought to play significant roles in health outcomes, their identification and quantification remains a challenge due to the lack of reference standards in biological fluids. Moreover, the metabolic fate of these compounds is characterized by a high degree of inter-individual variability, which is further complicated by factors such as enterohepatic recirculation and the diverse metabolic capabilities of the gut microbiota. Research has demonstrated that encapsulation technologies can influence the bioavailability of polyphenols, with different delivery systems such as hard capsules and soft gummies affecting the dissolution rates and systemic exposure of these bioactive compounds. Given these complexities, there is an increasing need to further elucidate the pharmacokinetic profiles of flavan-3-ols and their metabolites to optimize their health benefits. To this end, the investigators seek to conduct an open-label, randomized, 4-way crossover design with the aim to explore the bioavailability of GSE-derived flavan-3-ols from GSE and their related microbial metabolites and advance understanding of the bioactive properties of flavan-3-ols contributing to the development of more effective dietary strategies and functional food products.

Conditions

Healthy Nutrition

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: Polyphenol extract low dose (hard capsule)

\<2% flavanol monomer hard capsule

Group Type: EXPERIMENTAL

Polyphenol extract

Intervention Type: DIETARY_SUPPLEMENT

Single dose

Experimental: Polyphenol extract medium dose (hard capsule)

15% flavanol monomer hard capsule

Group Type: EXPERIMENTAL

Polyphenol extract

Intervention Type: DIETARY_SUPPLEMENT

Single dose

Experimental: Polyphenol extract medium dose (gummy)

15% flavanol monomer x2 gummy

Group Type: EXPERIMENTAL

Polyphenol extract

Intervention Type: DIETARY_SUPPLEMENT

Single dose

Experimental: Polyphenol extract high dose (hard capsule)

26% flavanol monomer hard capsule

Group Type: EXPERIMENTAL

Polyphenol extract

Intervention Type: DIETARY_SUPPLEMENT

Single dose

Interventions

Polyphenol extract

Single dose

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Males
• Aged 18-40 years at recruitment
• BMI ≥ 20 and < 30kg/m2
• Considered healthy based on their medical history and physical examination.
• Subjects capable of and willing to comply with the protocol and to give their written informed consent.

Exclusion Criteria

• Existing chronic disease including any; cardiovascular, neurological, gastric/intestinal, hepatic/pancreatic, renal or hematological diseases, obstructive cardiomyopathy, myocardial infarction, intracranial hypertension, diabetes mellitus (type I or II), chronic kidney disease, clinically significant arrhythmia, metabolic anomaly, ischaemia heart disease.
• Uncontrolled Hypertension (>160/100 mm Hg) or hypotension (<100/60mm Hg)
• Current use of any medication or narcotics within 2 weeks prior to study entry.
• Currently on a clinically prescribed diet regimen.
• Self-reported alcohol intake of >10 units/ week
• Have taken antibiotic therapy within the last 3 months
• Following any specific diet (vegetarian, vegan, etc.)
• Consumption of dietary supplement(s) currently or within 4 weeks prior to study entry (i.e. botanicals, vitamins, minerals, amino acids).
• Weight change > 10% of total body weight within the 6 months before entry to study.
• Any intolerance or allergy documented or suspected to one of the components of the study products.
• Having a psychological or linguistic inability to sign the informed consent; Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
• Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Ulster

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chris Gill

Role: PRINCIPAL_INVESTIGATOR

Ulster University

Locations

Ulster University,Human Intervention Studies UnitColeraine, Co. Londonderry BT521SA

Coleraine, Co. Londonderry, United Kingdom

Countries

United Kingdom

Other Identifiers

REC/24/0047

Identifier Type: -

Identifier Source: org_study_id